NASDAQ · AVLN
Avalyn Pharma Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AVLN: Nov 11, 2026
Avalyn Pharma Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.64.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.64 | $-0.64 | $-0.64 | 1 |
| Dec 2026 | $-0.67 | $-0.67 | $-0.67 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · MarketBeat- BNK Invest · Sep 28, 6:44 AM EDTAdd Up The Pieces: IHE Could Be Worth $116Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
- RTTNews · Sep 22, 3:24 AM EDTAvalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung Disease(RTTNews) – Avalyn Pharma Inc. (AVLN) reported that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02, a nebulized formulation of nintedanib, in healthy volunteers and patients with idiopathic pulmonary fibrosis.
- RTTNews · Sep 17, 1:40 AM EDTAvalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress(RTTNews) – Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the appointment of Robert (Bob) J. Meyer, a pulmonary physician and former senior U.S. Food and Drug Administration (FDA) executive, to its Board of Directors.
- RTTNews · Sep 9, 1:52 AM EDTAvalyn's AP01 Shows Broad Lung Distribution In ERS 2026 In-Silico Modeling Data(RTTNews) – Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company focused on inhaled therapies for respiratory diseases, presented new data at the European Respiratory Society (ERS) International Congress 2026, held between September 5 and 9 in Barcelona, Spain.
- RTTNews · Aug 12, 1:47 PM EDTAvalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed(RTTNews) – Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company developing inhaled therapies for serious and rare respiratory diseases, reported second-quarter 2026 financial results and provided business updates, highlighting the completion of enrollment in the
- RTTNews · Aug 10, 5:49 AM EDTBiotech Stocks At 52-Week Highs – HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE(RTTNews) – The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results.
- MarketBeat · Jun 5, 10:06 PM EDTAvalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data AheadAvalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopath
- BNK Invest · May 4, 10:55 AM EDTMonday 5/4 Insider Buying Report: AVLN, CSGPAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Friday, Avalyn Pharma's , Jill Carroll, made a $5.00M buy of AVLN, purchasing 2
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Avalyn Pharma Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.